Vigil Neuroscience Inc (NASDAQ:VIGL) Is Down -35.06 Percent Over The Past 30 Days: What’s Next?

In last trading session, Vigil Neuroscience Inc (NASDAQ:VIGL) saw 0.34 million shares changing hands with its beta currently measuring 1.68. Company’s recent per share price level of $2.50 trading at $0.2 or 8.70% at ring of the bell on the day assigns it a market valuation of $102.20M. That closing price of VIGL’s stock is at a discount of -142.4% from its 52-week high price of $6.06 and is indicating a premium of 16.8% from its 52-week low price of $2.08. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 117.39K if we extend that period to 3-months.

For Vigil Neuroscience Inc (VIGL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.46 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Vigil Neuroscience Inc (NASDAQ:VIGL) trade information

Upright in the green during last session for gaining 8.70%, in the last five days VIGL remained trading in the red while hitting it’s week-highest on Monday, 11/25/24 when the stock touched $2.50 price level, adding 23.31% to its value on the day. Vigil Neuroscience Inc’s shares saw a change of -26.04% in year-to-date performance and have moved -16.67% in past 5-day. Vigil Neuroscience Inc (NASDAQ:VIGL) showed a performance of -35.06% in past 30-days. Number of shares sold short was 0.51 million shares which calculate 5.31 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 11 to the stock, which implies a rise of 77.27% to its current value. Analysts have been projecting 11 as a low price target for the stock while placing it at a high target of 11. It follows that stock’s current price would drop -340.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -340.0% for stock’s current value.

Vigil Neuroscience Inc (VIGL) estimates and forecasts

Statistics highlight that Vigil Neuroscience Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -21.38% of value to its shares in past 6 months, showing an annual growth rate of 1.88% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Vigil Neuroscience Inc (NASDAQ:VIGL)’s Major holders

Insiders are in possession of 21.27% of company’s total shares while institution are holding 80.16 percent of that, with stock having share float percentage of 101.81%. Investors also watch the number of corporate investors in a company very closely, which is 80.16% institutions for Vigil Neuroscience Inc that are currently holding shares of the company. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the top institutional holder at VIGL for having 5.84 million shares of worth $23.35 million. And as of 2024-06-30, it was holding 14.6419 of the company’s outstanding shares.

The second largest institutional holder is NORTHPOND VENTURES, LLC, which was holding about 4.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.5722 of outstanding shares, having a total worth of $16.86 million.

On the other hand, Vanguard Total Stock Market Index Fund and abrdn Life Sciences Investors are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 620.14 shares of worth $1.53 million or 1.52% of the total outstanding shares. The later fund manager was in possession of 235.01 shares on Sep 30, 2024 , making its stake of worth around $0.58 million in the company or a holder of 0.57% of company’s stock.